Patent application number | Description | Published |
20090258018 | Methods for treating juvenile idiopathic arthritis - The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNFα inhibitor. | 10-15-2009 |
20090304682 | Multiple-variable dose regimen for treating TNFa-related disorders - Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. | 12-10-2009 |
20090317399 | Uses and compositions for treatment of CROHN'S disease - The invention provides methods, uses and compositions for the treatment of Crohn's disease. The invention describes methods and uses for treating Crohn's disease, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to induce and maintain remission of Crohn's disease in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of Crohn's disease in a subject. | 12-24-2009 |
20100028363 | METHODS FOR TREATING PSORIASIS - The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 02-04-2010 |
20100297143 | METHODS FOR TREATING PSORIASIS - The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 11-25-2010 |
20110206680 | METHODS FOR TREATING PSORIASIS - The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 08-25-2011 |
20120189637 | METHODS FOR TREATING PSORIASIS - The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 07-26-2012 |
20120219562 | METHODS OF TREATING PSORIASIS BY ADMINISTRATION OF ANTIBODIES TO THE p40 SUBUNIT OF IL-12 AND/OR IL-23 - The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 08-30-2012 |
20120225080 | HUMAN ANTIBODIES THAT BIND THE P40 SUBUNIT OF HUMAN IL-12/IL-23 AND USES THEREFOR - The invention provides human antibodies that bind to the p40 subunit of human IL-12 and/or IL-23. The invention further provides a method of treating psoriasis in a subject by administering to a subject an antibody that binds to the p40 subunit of IL-12 and/or IL-23. | 09-06-2012 |
20120263731 | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS - The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof. | 10-18-2012 |
20130122011 | Multiple-variable dose regimen for treating TNFa-related disorders - Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. | 05-16-2013 |
20140079714 | METHODS FOR TREATING PSORIASIS - The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 03-20-2014 |
20140093516 | HUMAN ANTIBODIES THAT BIND THE P40 SUBUNIT OF HUMAN IL-12/IL-23 AND USES THEREFOR - The invention provides human antibodies that bind to the p40 subunit of human IL-12 and/or IL-23. The invention further provides a method of treating psoriasis in a subject by administering to a subject an antibody that binds to the p40 subunit of IL-12 and/or IL-23. | 04-03-2014 |
20140377275 | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY FORMULATIONS - The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof. | 12-25-2014 |
Patent application number | Description | Published |
20080236119 | Exhaust gas particulate filter for a machine and filter cartridge therefor - An exhaust particulate filter for an engine system includes a housing having an inlet, an outlet and a shell shaped to fit the particulate filter within a predefined spatial envelope. Filter elements are arranged in a composite filter assembly and are packed within a housing. Each of the filter elements includes a cartridge having a frame wrapped with fibrous metallic filter media. The composite filter assembly has a shape corresponding to the shape of the shell. Each cartridge of the composite filter assembly is reversibly coupled with a frame internal of the shell via trapping elements having a release state and a trapping state. | 10-02-2008 |
20090139318 | SYSTEMS AND METHODS FOR MONITORING THE QUALITY OF A REDUCING AGENT - This patent disclosure relates to monitoring the quality of a reducing agent used in an emission-control system. Because emission-control systems may be used in extreme temperatures, the reducing agent used in these systems may be exposed to extreme temperatures for prolonged periods. This exposure may cause premature degradation of the reducing agent, thereby reducing the effectiveness of the emission-control system. To monitor the quality of the reducing agent, the disclosed systems and methods measure a property of the reducing agent, determine whether the measured property is out of compliance with a predetermined range, and provide a warning signal when the measured property is out of compliance. | 06-04-2009 |
20090188389 | Particulate filter for an exhaust aftertreatment system of a machine and filtering method thereof - A particulate filter includes a filter element comprising a non-perforated tube having an exhaust inlet at a first end and an exhaust outlet at a second end. A fibrous metallic filter medium is disposed within the filter element and is configured to trap particulate matter from an exhaust gas. A first metallic foam disk is attached at the second end of the filter element, and retains the fibrous metallic filter medium within the filter element. A second metallic foam disk may be attached at the first end of the filter element and may allow the particulate filter to be reversed with respect to an exhaust gas flow. | 07-30-2009 |
20100318471 | Systems and Methods for Monitoring the Quality of a Reducing Agent - This patent disclosure relates to monitoring the quality of a reducing agent used in an emission-control system. Because emission-control systems may be used in extreme temperatures, the reducing agent used in these systems may be exposed to extreme temperatures for prolonged periods. This exposure may cause premature degradation of the reducing agent, thereby reducing the effectiveness of the emission-control system. To monitor the quality of the reducing agent, the disclosed systems and methods measure a property of the reducing agent, determine whether the measured property is out of compliance with a predetermined range, and provide a warning signal when the measured property is out of compliance. | 12-16-2010 |
Patent application number | Description | Published |
20090056320 | Exhaust system having catalytically active particulate filter - A catalyst is disclosed. The catalyst contains a ternary nitride and at least one of gold, osmium, iridium, palladium, rhodium, rhenium, ruthenium, or cesium. The catalyst may be used for a particulate filter in an engine exhaust treatment system. | 03-05-2009 |
20090194741 | Exhaust system having a carbon oxide catalyst - A catalytic filter system is disclosed. The catalytic filter system contains a catalyst including a ternary nitride and at least one of gold, osmium, iridium, palladium, rhodium, rhenium, ruthenium, or cesium. The catalytic filter system may further include an energy source situated to impart energy to the catalyst. | 08-06-2009 |
20100154370 | SYSTEM AND METHODS FOR PARTICULATE FILTER - Various examples of system and methods for particulate filters include a particulate filter comprising a housing having a flow axis between an input header and an output header, and a plurality of filter segments arranged in a stacked array, the stacked array disposed within the housing and lying in a plane normal to the flow axis, the stacked array including a first filter segment having a first average flow characteristic per unit area and a second filter segment having a second average flow characteristic per unit area, the first average flow characteristic per unit area different from the second average flow characteristic per unit area, each particular filter segment of the plurality of filter segments having a segment flow axis substantially in parallel alignment with the flow axis. | 06-24-2010 |
20100154393 | Combination partial flow particulate filter and catalyst - The present disclosure is directed to a filtering element. The filtering element may comprise at least one channel defined by at least one wall. The at least one wall extends longitudinally from a first end of the channel to a second end of the channel, the at least one channel having an unobstructed first end and an unobstructed second end. The filtering element further includes at least one partial barrier configured to reduce a path of a flow of exhaust through the at least one channel, the at least one partial barrier being positioned within the at least one channel so as to redirect a portion of the exhaust flow within the channel. The at least one channel includes a selective catalytic reduction catalyst on at least a portion of one of a surface of the at least one partial barrier or a surface of the at least one wall. | 06-24-2010 |
20100329975 | Cordierite-Forming Compositions With Hydratable Alumina And Methods Therefor - A cordierite batch composition that includes a hydratable alumina, as defined herein. The hydratable alumina, when hydrated, can provide additional strength to shaped batch compositions at temperatures below those used to fire the compositions. Methods are also provided for forming cordierite ceramic articles from the cordierite batch compositions. | 12-30-2010 |